Education
About Us
Working with TipRanks
Follow Us
Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
Top Page
Amneal Pharmaceuticals
(NASDAQ:AMRX)62Neutral
Positive Factors
Business Positioning
AMRX's generics business is increasingly well-positioned with a portfolio more focused on complex products and biosimilars, supporting sustainable growth over the next several years.
Product Launch
With the Crexont launch off to a solid start and continued momentum elsewhere across the portfolio, analyst upgrades AMRX to OW from N.
Negative Factors
Market Caution
There is a more mixed view on Crexont and more caution than the Street on overall Gx fundamentals longer-term.
Amneal Pharmaceuticals (AMRX) vs. S&P 500 (SPY)
Market Cap
$2.76B
Dividend YieldN/A
Average Volume (3M)1.52M
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth16.73%
EPS Growth-22.44%
CountryUS
Employees7,700
SectorHealthcare
Sector Strength74
IndustryPharmaceuticals
Share Statistics
EPS (TTM)-0.38
Shares Outstanding309,966,340
10 Day Avg. Volume2,480,528
30 Day Avg. Volume1,515,925
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.99
Price to Cash Flow (P/CF)5.80
P/FCF Ratio5.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.33Price Target Upside27.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Amneal Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAmneal Pharmaceuticals (AMRX) is a global pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty pharmaceutical products. The company operates in the healthcare sector, primarily producing generic medications across a wide range of therapeutic areas. Additionally, Amneal is involved in the research and development of complex generics and biosimilars, aiming to provide cost-effective and accessible healthcare solutions.
How the Company Makes MoneyAmneal Pharmaceuticals generates revenue primarily through the sale of its generic and specialty pharmaceutical products. The company's key revenue streams include its generic drug portfolio, which covers a broad spectrum of therapeutic areas and is sold to wholesalers, distributors, and pharmacies. Amneal also invests in the development of complex generics and biosimilars, which can command higher prices and margins due to their complexity and limited competition. Partnerships and collaborations with other pharmaceutical companies and healthcare providers play a significant role in expanding the company's product offerings and market reach, contributing to its earnings. Additionally, Amneal's specialty pharmaceutical segment, which focuses on branded and niche products, offers another avenue for revenue growth.
Amneal Pharmaceuticals Financial Statement Overview
Summary
Amneal Pharmaceuticals shows a mixed financial picture. The company is experiencing revenue growth and improving gross margins, which are positive indicators. However, consistent net losses and a highly leveraged balance sheet present significant risks. Positive cash flows provide some operational stability, but the overall financial health is hindered by negative equity and profitability challenges.Income Statement
Amneal Pharmaceuticals has shown a solid revenue growth over the years, with Total Revenue increasing from $1.99 billion in 2020 to $2.79 billion in 2024. Gross Profit Margin has been improving, reaching approximately 36.5% in 2024. However, the company has struggled with profitability, as indicated by persistent negative Net Income in recent years, despite an improving EBIT Margin of 8.9% in 2024.65
Positive
Balance Sheet
The balance sheet of Amneal Pharmaceuticals indicates financial stress, with negative Stockholders' Equity in 2024 due to accumulated losses. The Debt-to-Equity ratio is not meaningful due to negative equity, but the high Total Debt of $331 million suggests significant leverage. The equity ratio turned negative in 2024, indicating liabilities exceed assets.40
Negative
Cash Flow
Amneal Pharmaceuticals has managed to generate positive Operating Cash Flow, reaching $295 million in 2024. Free Cash Flow has been positive, although declining from $276 million in 2023 to $243 million in 2024. The Free Cash Flow to Net Income ratio is not meaningful due to negative Net Income, but the positive cash flows indicate operational resilience.58
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.79B | 2.39B | 2.21B | 2.09B | 1.99B | Gross Profit |
| 1.02B | 820.57M | 784.71M | 768.97M | 628.39M | EBIT |
| 249.33M | 204.37M | 206.46M | 209.24M | 91.16M | EBITDA |
| 439.77M | 399.76M | 150.43M | 450.00M | 381.05M | Net Income Common Stockholders |
| -116.89M | -83.99M | -254.79M | 20.17M | 68.58M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 110.55M | 91.54M | 25.98M | 247.79M | 341.38M | Total Assets |
| 3.50B | 3.47B | 3.80B | 3.94B | 4.01B | Total Debt |
| 331.35M | 2.75B | 2.85B | 2.88B | 2.94B | Net Debt |
| 220.80M | 2.66B | 2.82B | 2.63B | 2.60B | Total Liabilities |
| 3.61B | 3.45B | 3.59B | 3.57B | 3.66B | Stockholders Equity |
| -109.27M | 19.78M | 183.98M | 366.97M | 344.93M |
| Cash Flow | Free Cash Flow | |||
| 243.18M | 276.39M | -25.50M | 189.18M | 312.81M | Operating Cash Flow |
| 295.10M | 345.58M | 65.10M | 241.82M | 379.00M | Investing Cash Flow |
| -63.00M | -69.19M | -174.31M | -194.18M | -317.55M | Financing Cash Flow |
| -211.79M | -212.57M | -106.62M | -138.12M | 131.81M |
Amneal Pharmaceuticals Technical Analysis
Positive
8.90
Price Trends
8.19
Positive
8.31
Positive
7.94
Positive
Market Momentum
0.20
Negative
64.95
Neutral
81.72
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Positive. The current price of 8.9 is above the 20-day moving average (MA) of 8.25, above the 50-day MA of 8.19, and above the 200-day MA of 7.94, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 64.95 is Neutral, neither overbought nor oversold. The STOCH value of 81.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMRX.
Amneal Pharmaceuticals Risk Analysis
Amneal Pharmaceuticals disclosed 53 risk factors in its most recent earnings report. Amneal Pharmaceuticals reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amneal Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $148.71B | 18.62 | 9.05% | 6.32% | 8.77% | 272.80% | |
68 Neutral | $3.91B | ― | -3.53% | 3.85% | -6.05% | -1677.05% | |
62 Neutral | $2.76B | ― | 106.97% | ― | 16.73% | -22.44% | |
59 Neutral | $3.73B | ― | 3.60% | ― | 11.61% | 92.72% | |
50 Neutral | $17.71B | ― | -25.44% | ― | 4.34% | -206.85% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% |
* Healthcare Sector Average
Performance Comparison
AMRX
Amneal Pharmaceuticals
8.90
3.52
65.43%
PRGO
Perrigo Company
27.76
-1.65
-5.61%
PFE
Pfizer
26.73
0.03
0.11%
TEVA
Teva Pharmaceutical
15.36
2.01
15.06%
TSE:BHC
Bausch Health Companies
10.15
-2.16
-17.55%
Amneal Pharmaceuticals Earnings Call Summary
Earnings Call Date: Feb 28, 2025 | % Change Since: 6.21% | Next Earnings Date: May 2, 2025
Earnings Call Sentiment Positive
Amneal Pharmaceuticals had a strong year with significant growth and successful new product launches, particularly Crexent. They made strategic entries into new markets and achieved financial improvements. However, challenges such as the upcoming Rytary loss of exclusivity and slow progress in the Naloxone market were noted.Highlights
Stellar Financial Performance in 2024
Amneal Pharmaceuticals delivered double-digit revenue and adjusted EBITDA growth in 2024, with net leverage reduced below four times.
Successful Launch of Crexent
Crexent was launched successfully, achieving about 1% market share in four months and projected to reach over 3% by year-end. Expected US peak sales are between $300 to $500 million.
Entry into High-Growth Weight Loss Market
Amneal entered the weight loss and obesity space through a strategic collaboration with Medcera, aiming to leverage the projected $150 billion global market by 2030.
Double-Digit Growth in All Segments
The affordable medicine segment grew by 15%, specialty by 14%, and RevCare by 25% in 2024.
Strong Q4 Revenue Growth
Q4 revenues grew by 18%, driven by new product launches and biosimilars, with biosimilars revenue increasing by 49%.
Deleveraging Success and Credit Rating Upgrade
Amneal reduced net leverage from 4.8 times to 3.9 times and received credit rating upgrades from S&P and Moody's.
Lowlights
Rytary Loss of Exclusivity
Rytary is expected to lose exclusivity in the third quarter of 2025, impacting its revenue contribution.
Naloxone Market Challenges
Progress in securing additional state contracts for Naloxone has been slow, with only California signed so far.
Company Guidance
During the Amneal Pharmaceuticals, Inc. fourth quarter 2024 earnings call, the company provided guidance for 2025, highlighting expectations for continued growth across its business segments. The company anticipates total net revenue for 2025 to reach between $3.0 to $3.1 billion, representing a growth of 7% to 11%. The affordable medicine segment is projected to maintain double-digit growth, driven by recent and upcoming product launches, as well as biosimilar and injectable expansions. The specialty segment is expected to generate approximately $400 million, with Crexent sales anticipated at around $50 million. Additionally, the RevCare segment is forecasted to continue its double-digit growth trajectory. Amneal also expects adjusted EBITDA between $650 and $675 million, a 4% to 8% increase, and plans to maintain adjusted gross margins between 41% to 42%. The company aims to reduce its net leverage to below four times, further enhancing its financial position.Amneal Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial Disclosures
Amneal Pharmaceuticals Reports Strong 2024 Financial Growth
Positive
Feb 28, 2025
Amneal Pharmaceuticals reported its financial results for the fourth quarter and full year of 2024, showing significant growth across all business segments. The company achieved a net revenue of $2.79 billion for the year, a 17% increase from 2023, driven by new product launches and growth in its Affordable Medicines, AvKARE, and Specialty segments. Despite a GAAP net loss of $117 million for the year, Amneal’s adjusted EBITDA increased by 12% to $627 million. The company also provided its 2025 financial guidance, projecting net revenue between $3.0 billion and $3.1 billion and adjusted EBITDA between $650 million and $675 million, indicating continued expansion in high-growth areas such as Specialty, Biosimilars, and GLP-1 therapies.
Regulatory Filings and Compliance
Amneal Pharmaceuticals Maintains Transparency with SEC Filing
Neutral
Jan 15, 2025
On January 15, 2025, Amneal Pharmaceuticals, Inc. announced a report filed under the Securities Exchange Act of 1934, signed by Anastasios Konidaris, the Executive Vice President and Chief Financial Officer. This release reflects the company’s adherence to regulatory requirements and maintains transparency with stakeholders.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.